Report overview
The global Long-acting Beta Agonists market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is Forecast to Reach $ Million.
Serevent Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Long-acting Beta Agonists include GSK, AstraZeneca, Chiesi, Boehringer Ingelheim, Novartis, Teva and Organon, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Long-Acting Beta Agonists (LABAs) are?inhaled medications that are used in the treatment of asthma and chronic obstuctive pulmonary disease (COPD).
This report aims to provide a comprehensive presentation of the global market for Long-acting Beta Agonists, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-acting Beta Agonists. This report contains market size and forecasts of Long-acting Beta Agonists in global, including the following market information:
Global Long-acting Beta Agonists Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global Long-acting Beta Agonists Market Sales, 2019-2024, 2025-2030, (K Units)
Global top five Long-acting Beta Agonists companies in 2023 (%)
We surveyed the Long-acting Beta Agonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Long-acting Beta Agonists Market, by Type, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Long-acting Beta Agonists Market Segment Percentages, by Type, 2023 (%)
Serevent
Foradil
Striverdi
Other
Global Long-acting Beta Agonists Market, by Application, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Long-acting Beta Agonists Market Segment Percentages, by Application, 2023 (%)
COPD
Asthma
Other
Global Long-acting Beta Agonists Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions) & (K Units)
Global Long-acting Beta Agonists Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Long-acting Beta Agonists revenues in global market, 2019-2024 (Estimated), ($ millions)
Key companies Long-acting Beta Agonists revenues share in global market, 2023 (%)
Key companies Long-acting Beta Agonists sales in global market, 2019-2024 (Estimated), (K Units)
Key companies Long-acting Beta Agonists sales share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
GSK
AstraZeneca
Chiesi
Boehringer Ingelheim
Novartis
Teva
Organon
Outline of Major Chapters:
Chapter 1: Introduces the definition of Long-acting Beta Agonists, market overview.
Chapter 2: Global Long-acting Beta Agonists market size in revenue and volume.
Chapter 3: Detailed analysis of Long-acting Beta Agonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Long-acting Beta Agonists in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Long-acting Beta Agonists capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
